NasdaqGS - Delayed Quote USD

Kamada Ltd. (KMDA)

5.15

-0.05

(-0.96%)

At close: April 26 at 4:00 PM EDT

KMDA: Double Digit Growth Anticipated in 2024 with $158 Million in Expected Revenues and $28 Million in Expected Adjusted EBITDA…

By David Bautz, PhD NASDAQ:KMDA READ THE FULL KMDA RESEARCH REPORT Financial Update On March 6, 2024, Kamada Ltd. (NASDAQ:KMDA) announced financial results for the fourth quarter and full year 2023 and provided a business update. Kamada reported revenues of $142.5 million, which met the company’s previously announced guidance, and was a 10% increase compared to fiscal year 2022. The increase was

Zacks Small Cap Research last month

KMDA.TA
Kamada Ltd. (NASDAQ:KMDA) Q4 2023 Earnings Call Transcript

Kamada Ltd. (NASDAQ:KMDA) Q4 2023 Earnings Call Transcript March 6, 2024 Kamada Ltd. beats earnings expectations. Reported EPS is $0.09, expectations were $0.05. KMDA isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Greetings. Welcome to Kamada Ltd.’s Fourth Quarter and […]

Insider Monkey last month

KMDA.TA
Kamada Issues 2024 CEO Letter to Shareholders

REHOVOT, Israel, and HOBOKEN, N.J., March 06, 2024 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today issued a Letter to Shareholders from Amir London, Chief Executive Officer. Dear Shareholders, Colleagues and Business Partners: The recently completed 2023 was another successful period in our com

GlobeNewswire last month

KMDA
-0.96%
Kamada Reports Strong Fiscal Year and Fourth Quarter 2023 Financial Results, and Provides Full-Year 2024 Guidance Representing Double-Digit Growth in Revenue and Profitability

Total Revenues for Fiscal Year 2023 of $142.5 Million, Representing All-Time Record Annual Revenues and Up 10% Compared to Fiscal Year 2022Fiscal Year 2023 Adjusted EBITDA of $24.1 Million, Up 35% Year-over-YearStrong Momentum Supports Expected Double-Digit Growth with Anticipated Fiscal Year 2024 Revenues in Range of $156 to $160 Million and Expected Adjusted EBITDA in Range of $27 to $30 MillionKamada Maintains Financial Strength to Accelerate Growth and Pursue Compelling New Business Developm

GlobeNewswire last month

KMDA
-0.96%
Kamada to Announce Fourth Quarter and Fiscal Year 2023 Financial Results, and Provide 2024 Financial Guidance on March 6, 2024

Company to Host Conference Call at 8:30am ETREHOVOT, Israel, and HOBOKEN, N.J., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that it will release financial results for the fourth quarter and fiscal year ended December 31, 2023, as well as provide 2024 financial guidan

GlobeNewswire last month

KMDA
-0.96%
KEDRION ANNOUNCES AN EIGHT-YEAR EXTENSION OF THE DISTRIBUTION AGREEMENT WITH KAMADA IN THE US FOR KEDRAB®

Kedrion Biopharma, a leading global biopharmaceutical company that develops, manufactures and commercializes therapeutic products derived from blood plasma, announces the execution of a binding memorandum of understanding with Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), an Israeli commercial stage global biopharmaceutical company and leader in the specialty plasma-derived field, for the amendment and the 8-year extension of the KEDRAB® US distribution agreement between the two companies.

PR Newswire 4 months ago

TVAVF

KMDA
-0.96%
KMDA: Amendment and Extension of Kedrab® U.S. Distribution Agreement to Generate at Least $180 Million Over First Four Years…

By David Bautz, PhD NASDAQ:KMDA READ THE FULL KMDA RESEARCH REPORT Business Update On December 6, 2023, Kamada Ltd. (NASDAQ:KMDA) announced the execution of a binding memorandum of understanding with Kedrion for an amendment and extension of the company’s U.S. distribution agreement for Kedrab, a human rabies immune globulin indicated for the transient post-exposure prophylaxis of rabies

Zacks Small Cap Research 4 months ago

KMDA.TA
Kamada Announces its Largest Commercial Agreement; A Strategic Engagement with Kedrion for U.S. Distribution of KEDRAB® including $180 Million of Revenues Over First Four Years

Largest Commercial Agreement in Kamada’s History Becomes Effective in January 2024 and Includes $180 Million of Revenues to Kamada Over the First Four Years of the Eight Year TermFinancial Terms Reflect KEDRAB®'s Significant U.S. Market Share and Continued Growth Through the Eight Year TermAgreement Includes Potential Expansion of Kedrion’s Distribution of KEDRAB in Additional Territories Beyond the U.S.Kamada to Host a Conference Call and Live Webcast Today at 8:30 AM ET REHOVOT, Israel and HOB

GlobeNewswire 4 months ago

KMDA
-0.96%
KMDA: $37.9 Million in 3Q23 Revenues; Closes $60 Million Private Placement with FIMI Opportunity Funds…

By David Bautz, PhD NASDAQ:KMDA READ THE FULL KMDA RESEARCH REPORT Financial Update On November 13, 2023, Kamada Ltd. (NASDAQ:KMDA) announced financial results for the third quarter of 2023. Kamada reported revenues of $37.9 million, which was a 18% increase over the third quarter of 2022. The revenue consisted of $31.4 million from proprietary products and $6.5 million from the distribution

Zacks Small Cap Research 5 months ago

KMDA.TA
Kamada Reports Significant Increase in Sales and Profitability in the Third Quarter and Nine Month 2023; Reiterates 2023 Revenue and Profitability Guidance

Third Quarter 2023 Revenues were $37.9 Million Representing an 18% Increase Year-over-Year; Nine Month 2023 Revenues of $106.1 Million, Up 26% Year-over-YearThird Quarter 2023 Adjusted EBITDA of $7.9 Million Representing a 31% Increase Year-over-Year; Nine Month 2023 Adjusted EBITDA of $17.7 Million, Up 67% Year-over-YearStrong Third Quarter Results and Positive Outlook for Fourth Quarter Support Reiteration of Fiscal Year 2023 Revenue and Adjusted EBITDA Guidance Multiple Recent Achievements wi

GlobeNewswire 5 months ago

KMDA
-0.96%
Kamada to Announce Third Quarter and First Nine Months Ended September 30, 2023 Financial Results and Host Conference Call on November 13, 2023

REHOVOT, Israel, and HOBOKEN, N.J., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that it will release financial results for the third quarter and first nine months ended September 30, 2023, prior to the open of the U.S. financial markets on Monday, November 13, 2023. Kamada m

GlobeNewswire 5 months ago

KMDA
-0.96%
Kamada Announces Recent Achievements with CYTOGAM® including Availability of Product Manufactured by the Company for U.S Commercial Sale and Presentation of New Clinical Data

Following Recent FDA Approval of Technology Transfer Process, CYTOGAM® Manufactured by Kamada at its Facility Now Available for Commercial Sales in U.S.New Clinical Data Highlighting Five-year Real-world Survival Benefits of High Risk CMV Mismatch Lung Transplant Patients Receiving CYTOGAM were Presented at IDWeek 2023Company Establishes Scientific Advisory Board Focused on U.S. Clinical Programs for CYTOGAM REHOVOT, Israel and HOBOKEN, N.J., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ

GlobeNewswire 6 months ago

KMDA
-0.96%
Kamada Provides Corporate Update on its Israel Operations

REHOVOT, Israel, and HOBOKEN, N.J., Oct. 10, 2023 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that while circumstances in Israel are evolving, the Company continues to conduct its business operations in Israel with no effect on business continuity, and its global supply of product

GlobeNewswire 6 months ago

KMDA
-0.96%
Kamada Announces Shareholder Approval and Planned Closing of $60 Million Private Placement with FIMI Opportunity Funds

Funding Strengthens Kamada’s Financial Position, Supporting its Growth Plans and the Pursuit of Strategic Business Development OpportunitiesAppointment of Two New Independent Directors to its Board: Professor Benjamin Dekel and Mr. Assaf Itshayek REHOVOT, Israel and HOBOKEN, N.J., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a lea

GlobeNewswire 7 months ago

KMDA
-0.96%
KMDA: 2Q23 Revenues up 59% YoY; Reiterates 2023 Revenue Guidance of $138 Million to $146 Million…

By David Bautz, PhD NASDAQ:KMDA READ THE FULL KMDA RESEARCH REPORT Financial Update On August 22, 2023, Kamada Ltd. (NASDAQ:KMDA) announced financial results for the second quarter of 2023. Kamada reported revenues of $37.4 million, which was a 59% increase over the second quarter of 2022. The revenue consisted of $30.9 million from proprietary products and $6.5 million from the distribution

Zacks Small Cap Research 8 months ago

KMDA.TA
Kamada Reports Strong Second Quarter and First Half 2023 Financial Results; Reiterates 2023 Revenue and Profitability Guidance

Second Quarter 2023 Revenues were $37.4 Million, Representing a 59% Increase Year-over-Year; First Half 2023 Revenues of $68.2 Million, Up 32% Year-over-YearFirst Half 2023 Adjusted EBITDA of $9.9 Million, Up 24% Year-over-Year Robust Second Quarter Results and Positive Outlook for Second Half of 2023 Support Reiteration of Fiscal Year 2023 Revenue Guidance of $138 Million - $146 Million, and Adjusted EBITDA of $22 Million to $26 Million Extended U.S. Distribution Agreement for KEDRAB® Rabies Im

GlobeNewswire 8 months ago

KMDA
-0.96%
Kamada to Announce Second Quarter and First Half Ended June 30, 2023 Financial Results and Host Conference Call on August 16, 2023

REHOVOT, Israel and HOBOKEN, N.J., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that it will release financial results for the second quarter and first half ended June 30, 2023, prior to the open of the U.S. financial markets on Wednesday, August 16, 2023. Kamada management w

GlobeNewswire 8 months ago

KMDA
-0.96%
Kamada Announces Kedrion Exercised its Option for Two-Year Extension of KEDRAB® Distribution Agreement in the U.S.

The Extended Agreement Term is Until March 2026The Company Generated Approximately $16 Million in Revenue from Sales of KEDRAB to Kedrion in 2022 and Anticipates a Significant Increase in 2023 REHOVOT, Israel, and HOBOKEN, N.J., July 12, 2023 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA) (“Kamada” or the “Company”), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plas

GlobeNewswire 9 months ago

KMDA
-0.96%
KMDA: 1Q23 Revenues of $30.7 Million; Continue to Expect 2023 Revenues of $138 Million to $146 Million…

By David Bautz, PhD NASDAQ:KMDA READ THE FULL KMDA RESEARCH REPORT Financial Update On May 24, 2023, Kamada Ltd. (NASDAQ:KMDA) announced financial results for the first quarter of 2023. Kamada reported revenues of $30.7 million, which was a 9% increase over the first quarter of 2022. The revenue consisted of $24.1 million from proprietary products and $6.6 million from the distribution business.

Zacks Small Cap Research 10 months ago

KMDA.TA
Kamada Reports Strong First Quarter 2023 Financial Results; Reiterates Revenue and Profitability Guidance

Total Revenues for First Quarter of 2023 were $30.7 Million, Up 9% Year-over-YearFirst Quarter 2023 EBITDA of $3.8 Million, Increase of 16% Year-over-YearSolid First Quarter Results and Expected Continued Momentum Supported by Multiple Growth Drivers Anticipated to Drive Full-Year 2023 EBITDA Growth of Over 30% Year-over-YearAnnounced $60 Million Private Placement with FIMI Opportunity FundsReceived FDA Approval to Manufacture CYTOGAM® at the Company’s Israeli Facility; Expected to Positively Im

GlobeNewswire 10 months ago

KMDA
-0.96%

Performance Overview

Return	KMDA	TA-125
YTD	-15.85%	+3.84%
1-Year	+14.96%	+12.73%
3-Year	-14.88%	+14.62%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Kamada Ltd. (KMDA)

KMDA: Double Digit Growth Anticipated in 2024 with $158 Million in Expected Revenues and $28 Million in Expected Adjusted EBITDA…

Kamada Ltd. (NASDAQ:KMDA) Q4 2023 Earnings Call Transcript

Kamada Issues 2024 CEO Letter to Shareholders

Kamada Reports Strong Fiscal Year and Fourth Quarter 2023 Financial Results, and Provides Full-Year 2024 Guidance Representing Double-Digit Growth in Revenue and Profitability

Kamada to Announce Fourth Quarter and Fiscal Year 2023 Financial Results, and Provide 2024 Financial Guidance on March 6, 2024

KEDRION ANNOUNCES AN EIGHT-YEAR EXTENSION OF THE DISTRIBUTION AGREEMENT WITH KAMADA IN THE US FOR KEDRAB®

KMDA: Amendment and Extension of Kedrab® U.S. Distribution Agreement to Generate at Least $180 Million Over First Four Years…

Kamada Announces its Largest Commercial Agreement; A Strategic Engagement with Kedrion for U.S. Distribution of KEDRAB® including $180 Million of Revenues Over First Four Years

KMDA: $37.9 Million in 3Q23 Revenues; Closes $60 Million Private Placement with FIMI Opportunity Funds…

Kamada Reports Significant Increase in Sales and Profitability in the Third Quarter and Nine Month 2023; Reiterates 2023 Revenue and Profitability Guidance

Kamada to Announce Third Quarter and First Nine Months Ended September 30, 2023 Financial Results and Host Conference Call on November 13, 2023

Kamada Announces Recent Achievements with CYTOGAM® including Availability of Product Manufactured by the Company for U.S Commercial Sale and Presentation of New Clinical Data

Kamada Provides Corporate Update on its Israel Operations

Kamada Announces Shareholder Approval and Planned Closing of $60 Million Private Placement with FIMI Opportunity Funds

KMDA: 2Q23 Revenues up 59% YoY; Reiterates 2023 Revenue Guidance of $138 Million to $146 Million…

Kamada Reports Strong Second Quarter and First Half 2023 Financial Results; Reiterates 2023 Revenue and Profitability Guidance

Kamada to Announce Second Quarter and First Half Ended June 30, 2023 Financial Results and Host Conference Call on August 16, 2023

Kamada Announces Kedrion Exercised its Option for Two-Year Extension of KEDRAB® Distribution Agreement in the U.S.

KMDA: 1Q23 Revenues of $30.7 Million; Continue to Expect 2023 Revenues of $138 Million to $146 Million…

Kamada Reports Strong First Quarter 2023 Financial Results; Reiterates Revenue and Profitability Guidance

Performance Overview